Rise Advisors LLC Acquires 203 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Rise Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2,255.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 212 shares of the specialty pharmaceutical company’s stock after acquiring an additional 203 shares during the quarter. Rise Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $26,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock valued at $825,705,000 after purchasing an additional 29,960 shares during the last quarter. FMR LLC raised its stake in shares of Jazz Pharmaceuticals by 8.1% in the third quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock valued at $172,560,000 after acquiring an additional 100,349 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,299,612 shares of the specialty pharmaceutical company’s stock worth $168,222,000 after acquiring an additional 57,717 shares during the last quarter. Polaris Capital Management LLC boosted its stake in shares of Jazz Pharmaceuticals by 2.2% during the 4th quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock worth $155,898,000 after purchasing an additional 27,100 shares during the period. Finally, Pacer Advisors Inc. grew its holdings in Jazz Pharmaceuticals by 28.1% during the 4th quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after purchasing an additional 224,865 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Piper Sandler boosted their target price on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They issued a “buy” rating and a $169.00 target price on the stock. Stifel Nicolaus boosted their target price on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Finally, UBS Group reduced their price target on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research note on Friday, March 1st. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $190.00.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $107.97 on Friday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The company has a 50 day moving average price of $109.08 and a 200-day moving average price of $117.23. Jazz Pharmaceuticals plc has a fifty-two week low of $103.01 and a fifty-two week high of $146.70. The stock has a market capitalization of $6.81 billion, a PE ratio of 22.26, a PEG ratio of 1.73 and a beta of 0.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The company had revenue of $901.98 million for the quarter, compared to analysts’ expectations of $938.99 million. Equities analysts predict that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the business’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the transaction, the executive vice president now directly owns 36,629 shares in the company, valued at $4,016,369.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.40% of the stock is owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.